These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 14500382)

  • 1. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
    Sattler M; Pride YB; Ma P; Gramlich JL; Chu SC; Quinnan LA; Shirazian S; Liang C; Podar K; Christensen JG; Salgia R
    Cancer Res; 2003 Sep; 63(17):5462-9. PubMed ID: 14500382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
    Ma PC; Schaefer E; Christensen JG; Salgia R
    Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
    Rodrigues GA; Park M
    Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus.
    Fixman ED; Naujokas MA; Rodrigues GA; Moran MF; Park M
    Oncogene; 1995 Jan; 10(2):237-49. PubMed ID: 7838524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.
    Berthou S; Aebersold DM; Schmidt LS; Stroka D; Heigl C; Streit B; Stalder D; Gruber G; Liang C; Howlett AR; Candinas D; Greiner RH; Lipson KE; Zimmer Y
    Oncogene; 2004 Jul; 23(31):5387-93. PubMed ID: 15064724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-Met is a potentially new therapeutic target for treatment of human melanoma.
    Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
    Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.
    Zimmer Y; Vaseva AV; Medová M; Streit B; Blank-Liss W; Greiner RH; Schiering N; Aebersold DM
    Cancer Lett; 2010 Mar; 289(2):228-36. PubMed ID: 19783361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of tyrosine 489 in the carboxy terminus of the Tpr-Met oncoprotein as a major site of autophosphorylation.
    Kamikura DM; Naujokas MA; Park M
    Biochemistry; 1996 Jan; 35(3):1010-7. PubMed ID: 8547236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors.
    Accornero P; Lattanzio G; Mangano T; Chiarle R; Taulli R; Bersani F; Forni PE; Miretti S; Scuoppo C; Dastrù W; Christensen JG; Crepaldi T; Ponzetto C
    Clin Cancer Res; 2008 Apr; 14(7):2220-6. PubMed ID: 18381964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
    Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
    Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.
    Yamamoto N; Mammadova G; Song RX; Fukami Y; Sato K
    J Cell Sci; 2006 Nov; 119(Pt 22):4623-33. PubMed ID: 17062641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
    Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
    Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor.
    Jeffers M; Koochekpour S; Fiscella M; Sathyanarayana BK; Vande Woude GF
    Oncogene; 1998 Nov; 17(21):2691-700. PubMed ID: 9840933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis.
    Bertotti A; Comoglio PM; Trusolino L
    Cancer Res; 2005 Dec; 65(23):10674-9. PubMed ID: 16322210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
    Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
    Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The human met oncogene is a member of the tyrosine kinase family.
    Gonzatti-Haces M; Park M; Dean M; Blair DG; Vande Woude GF
    Princess Takamatsu Symp; 1986; 17():221-32. PubMed ID: 3332011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
    Christensen JG; Burrows J; Salgia R
    Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.